In the News
-
December 01, 2022
Drug Development & DeliveryLeveraging the Human Gut as a Drug Discovery Tool
-
July 22, 2022
New Haven BizArtizan to collaborate with European researchers on cancer therapy
-
June 30, 2022
CT InsiderNew Haven bioscience center adds another tenant
-
June 28, 2022
Patch New HavenBioscience Biz Artizan Inks Deal To Call Winchester Works Its New Home
-
June 28, 2022
New Haven BizArtizan Biosciences Leases Space at Winchester Works
-
February 07, 2022
New Haven BizPower 25 – Class of 2022
-
January 19, 2022
New Haven BizArtizan Biosciences picks lead inflammatory bowel disease candidate
-
November 23, 2021
New Haven BizArtizan, Biohaven join forces for Parkinson’s disease fight
-
October 22, 2021
Medical Marketing and MediaArtizan Biosciences appoints new president and CEO
-
October 22, 2021
Fierce BiotechChutes & Ladders
-
October 22, 2021
Endpoint NewsBridget Martell on taking Yale spinout ‘to adulthood’
-
October 22, 2021
BiospaceBioSpace Movers & Shakers
-
October 19, 2021
New Haven BizArtizan Biosciences names new CEO
-
March 04, 2021
New Haven RegisterNew Haven connection: One Elm City biotech invests in another
-
March 01, 2021
Endpoints NewsPrecision inflammation drugs? Yale spinout Artizan clinches $11M and Biohaven deal to single out bad bacteria
-
March 01, 2021
New Haven BizNew Haven’s Artizan Biosciences raises $11M; inks licensing deal with Biohaven
-
June 11, 2019
BioWorldGut instinct: Artizan completes series A to hit $12M in funding
-
June 11, 2019
Connecticut PostNew Haven IBD startup raises $12M
-
June 10, 2019
Endpoints NewsArtizan completes microbiome starter package with Brii deal, CSO hire and some money to dash for the clinic
-
June 10, 2019
XconomyWith Yale Tech and $12M, Artizan Aims for Root Cause of Gut Disease